Kinevant Sciences Announces First Patient Dosed in Phase 2 Study of Namilumab for the Treatment of Pulmonary Sarcoidosis (RESOLVE-Lung)

NEW YORK & BASEL, Switzerland--(BUSINESS WIRE)-- Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare autoimmune and inflammatory diseases, today announced that the first patient has been dosed in its RESOLVE-Lung study. This Phase 2 clinical study will evaluate the efficacy and safety of Kinevant’s namilumab for the treatment of pulmonary sarcoidosis. Namilumab is a human monoclonal antibody that targets granulocyte-macrophage colony stimulating factor (GM-CSF), one of the key cytokines believed to be responsible for granuloma formation and persistence in sarcoidosis.

Sarcoidosis is a rare, chronic inflammatory disease that affects approximately 200,000 people in the U.S. and 1.2 million worldwide.ⁱ Approximately 90% of patients have pulmonary sarcoidosis which is characterized by the accumulation of granulomas, or small clusters of immune cells, in the lungs, potentially leading to enlarged lymph nodes, pulmonary hypertension, and fibrosis.ⁱⁱ Pulmonary sarcoidosis can result in breathlessness, fatigue, cough, pain, and overall poor quality of life. In 20-30% of cases lung damage is permanent, and patients may require transplantation.

“Pulmonary sarcoidosis patients are frequently treated with oral corticosteroids, yet only half will experience symptom resolution after one or two courses, leaving those who do not respond with no other option than to continue on oral steroids or try other immunosuppressive therapies off-label,” explained Bill Gerhart, chief executive officer of Kinevant Sciences. “Steroids for long-term disease management can be challenging for patients because of significant negative side effects, and other immunosuppressive therapies are often not effective and/or poorly tolerated. We are excited to advance namilumab as a promising new treatment for pulmonary sarcoidosis since it has a mechanism of action that we believe targets the underlying sarcoidosis disease pathology and an established safety and tolerability profile, having been previously evaluated in more than 300 trial participants.”

RESOLVE-Lung is a Phase 2 randomized, double-blind, placebo-controlled study with an open-label extension (OLE) being conducted at multiple sites in the U.S. and Europe. The study will assess the efficacy and safety of namilumab in approximately 100 patients with pulmonary sarcoidosis across a 26-week treatment period. Namilumab or placebo will be administered subcutaneously every four weeks through week 22 after the initial dosing period. All patients that complete the 26-week double-blind treatment period will be eligible to participate in a 28-week OLE treatment period on namilumab.

“Rare inflammatory diseases, including sarcoidosis, are complex disorders that are challenging to diagnose and difficult to treat as there are limited, often ineffective treatment options,” said Divya Patel, D.O., associate professor of medicine, sarcoid program director and interstitial lung disease program director at University of Florida. “Namilumab has the potential to address the underlying mechanisms associated with sarcoidosis. Many patients with sarcoidosis experience poor quality of life, leading to death in some cases. Halting granuloma formation and associated inflammation has greater potential to prevent organ dysfunction and failure, while also maintaining a better quality of life, than is possible with current treatment options.”

About Namilumab

Namilumab is an investigational, novel fully human monoclonal antibody conveniently administered once a month as a subcutaneous injection. Namilumab is a potent GM-CSF inhibitor that has been well-tolerated so far in more than 300 participants across multiple clinical trials.ⁱⁱⁱ

About RESOLVE-Lung

The RESOLVE-Lung study is a Phase 2 clinical trial evaluating namilumab for the treatment of pulmonary sarcoidosis. Patients who qualify and agree to participate in the study will receive a once monthly injection of namilumab or placebo (following the initial dosing period) for approximately six months. This is a double-blind study, which means neither patients nor doctors and their staff will know which patients are receiving namilumab or placebo. Regardless of receiving namilumab or a placebo during the six-month double-blind treatment period, participants who complete the double-blind treatment period will be eligible to receive namilumab during a six-month OLE period. More information can be found at www.sarcoidosistrial.com.

About Kinevant Sciences

Kinevant Sciences, a subsidiary of Roivant Sciences, is a clinical-stage biopharmaceutical company developing new medicines for rare autoimmune and inflammatory diseases. The company takes a patient-first approach to drug development, advancing candidates with the potential to resolve the underlying disease and create life-changing benefit for patients. Kinevant is initially focusing on sarcoidosis with an anti-GM-CSF monoclonal antibody, namilumab, currently being evaluated in the Phase 2 RESOLVE-Lung study in patients with pulmonary sarcoidosis. Topline results are expected in the first half of 2024. For more information, visit www.kinevant.com.

About Roivant Sciences

Roivant’s mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch ‘Vants’ – nimble and focused biopharmaceutical and health technology companies. For more information, please visit www.roivant.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005290/en/